Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China | BMJ Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

For authors

About

Browse by collection
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Health economics

Original research

Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China

Online download statistics by month:

Online download statistics by month: August 2022 to April 2024

	Abstract	Full	Pdf
Aug 2022	662	661	24
Sep 2022	232	228	14
Oct 2022	511	513	81
Nov 2022	304	304	28
Dec 2022	324	323	13
Jan 2023	224	224	9
Feb 2023	23	22	14
Mar 2023	28	26	15
Apr 2023	18	18	14
May 2023	16	15	11
Jun 2023	24	23	16
Jul 2023	22	20	17
Aug 2023	24	21	14
Sep 2023	15	14	6
Oct 2023	31	31	7
Nov 2023	24	24	8
Dec 2023	28	28	15
Jan 2024	27	26	9
Feb 2024	28	28	19
Mar 2024	24	24	48
Apr 2024	27	27	31
Total	2616	2600	413